Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozdeutinurad in Tophaceous Gout
NCT05253833Phase 2Completed
- Sponsor
- Arthrosi Therapeutics
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of pozdeutinurad in gout (3 arms), sponsored by Arthrosi Therapeutics. Primary endpoint: Serum Urate Level < 5 mg/dL at 12 weeks. Started Aug 2022; status: completed.
02
Drugs
pozdeutinurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT05253833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05253833.